LRMR · Larimar Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $25.03M | - | $44.93M | $23.37M | $26.55M | - | $13.92M | $19.68M | $12.94M | - |
| SG&A | $6.09M | - | $4.57M | $4.42M | $4.64M | - | $4.34M | $4.92M | $3.79M | - |
| Total Operating Expenses | $31.12M | - | $49.50M | $27.79M | $31.19M | - | $18.26M | $24.60M | $16.73M | - |
| D&A | $64.0K | - | - | - | $88.0K | - | - | - | $80.0K | - |
| Operating Income | ($31.12M) | - | ($49.50M) | ($27.79M) | ($31.19M) | - | ($18.26M) | ($24.60M) | ($16.73M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | $0 | $0 | - | - | - | - | - | - |
| Net Income | ($29.61M) | - | ($47.71M) | ($26.18M) | ($29.28M) | - | ($15.50M) | ($21.63M) | ($14.65M) | - |
| EPS - Basic | - | - | ($0.61) | ($0.41) | ($0.46) | - | ($0.24) | ($0.34) | ($0.27) | - |
| EPS - Diluted | - | - | ($0.61) | ($0.41) | ($0.46) | - | ($0.24) | ($0.34) | ($0.27) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $177.91M | $85.41M | $90.14M | $20.59M | $21.13M | $33.22M | $35.07M | $32.31M | $110.13M | $26.75M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.58M | $5.22M | $11.10M | $4.17M | $2.27M | $2.42M | $1.69M | $2.92M | $1.92M | $1.28M |
| Current Assets | $204.98M | $142.02M | $183.22M | $145.56M | $165.49M | $195.30M | $213.26M | $231.13M | $230.95M | $90.17M |
| Total Assets | $208.51M | $145.84M | $187.35M | $149.99M | $170.18M | $200.22M | $219.02M | $237.16M | $248.21M | $95.94M |
| Current Liabilities | $47.76M | $64.80M | $45.12M | $26.65M | $22.13M | $24.36M | $16.29M | $21.16M | $12.84M | $9.51M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $50.48M | $67.76M | $48.31M | $30.13M | $25.90M | $28.41M | $20.62M | $25.76M | $17.36M | $14.21M |
| Stockholders' Equity | $158.03M | $78.08M | $139.04M | $119.85M | $144.27M | $171.81M | $198.40M | $211.40M | $230.84M | $81.72M |
| Retained Earnings | ($464.44M) | ($434.83M) | ($372.33M) | ($324.62M) | ($298.44M) | ($269.16M) | ($240.33M) | ($224.84M) | ($203.21M) | ($188.55M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($44.61M) | - | - | - | ($26.54M) | - | - | - | ($10.41M) | - |
| Investing Cash Flow | $29.00M | - | - | - | $14.45M | - | - | - | ($68.36M) | - |
| Financing Cash Flow | $108.11M | - | - | - | - | - | - | - | $162.15M | - |
| CapEx | - | - | - | - | $49.0K | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | ($26.59M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 0.91 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -14.2% | - | -25.5% | -17.5% | -17.2% | - | -7.1% | -9.1% | -5.9% | - |
| Return on equity | -18.7% | - | -34.3% | -21.8% | -20.3% | - | -7.8% | -10.2% | -6.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.29 | 2.19 | 4.06 | 5.46 | 7.48 | 8.02 | 13.10 | 10.93 | 17.99 | 9.49 |
| Quick ratio | 4.29 | 2.19 | 4.06 | 5.46 | 7.48 | 8.02 | 13.10 | 10.93 | 17.99 | 9.49 |
| Cash ratio | 3.73 | 1.32 | 2.00 | 0.77 | 0.95 | 1.36 | 2.15 | 1.53 | 8.58 | 2.81 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.32 | 1.87 | 1.35 | 1.25 | 1.18 | 1.17 | 1.10 | 1.12 | 1.08 | 1.17 |
| Liabilities / Assets | 0.24 | 0.46 | 0.26 | 0.20 | 0.15 | 0.14 | 0.09 | 0.11 | 0.07 | 0.15 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 1.8x | 1.5x | 1.0x | - | 2.1x | 2.2x | 1.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 0.2% | - | -171.0% | -13.0% | -86.4% | - | -76.7% | -155.7% | -119.1% | - |
| Net income growth (YoY) | -1.1% | - | -207.8% | -21.1% | -99.8% | - | -71.0% | -158.5% | -124.5% | - |
| EPS growth (YoY) | - | - | -154.2% | -20.6% | -70.4% | - | -14.3% | -78.9% | -80.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 9.5% | -54.6% | -29.9% | -43.3% | -37.5% | 110.2% | 114.0% | 111.6% | 117.3% | -26.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Larimar Therapeutics against the 5 most active filers in the same SIC group.